IP Library Granted Patent US 8,353,829
Granted Patent B2
US 8,353,829 · App. 12/643,975 · Granted Jan 15, 2013

Analyte monitoring device and methods of use

Inventors: James Say (Alameda, CA); Michael F. Tomasco (Cupertino, CA); Adam Heller (Austin, TX); Yoram Gal (Kibbutz Yagur, IL); Behrad Aria (Alameda, CA); Ephraim Heller (Oakland, CA); Phillip John Plante (Sunnyvale, CA); Mark S. Vreeke (Alameda, CA); Keith A. Friedman (Austin, TX); Fredric C. Colman (Berkeley, CA)
Assignee: Abbott Diabetes Care Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,353,829
App. No.
12/643,975
Granted
Jan 15, 2013
Kind
B2
Abstract

An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

Claims (19)

1. A method of communicating glucose information, comprising:

receiving a plurality of analyte related signals detected by an analyte sensor using a wireless communication protocol;

processing the received plurality of analyte related signals to generate glucose data and to determine an acceleration of analyte level increase or decrease reaching or exceeding a threshold value; and

transmitting the generated glucose data and/or an indication associated with the determined acceleration of the analyte level increase or decrease reaching or exceeding the threshold value using a telephone connection.

2. The method of claim 1 wherein the wireless communication protocol includes one of an RF communication protocol, or optical communication protocol.

3. The method of claim 1 further including outputting the generated glucose data.

4. The method of claim 3 wherein outputting the generated glucose data includes outputting one or more of a visual output, an audible output, or a vibratory output.

5. The method of claim 4 wherein the visual output includes one or more of a graphical output, a text output or a numerical output.

6. The method of claim 1 further including determining a dose of medication based at least in part on the generated glucose data.

7. The method of claim 6 wherein the medication includes insulin.

8. The method of claim 6 further including outputting the determined dose of medication.

9. The method of claim 6 further including transmitting the determined dose of medication to a drug administration system.

10. The method of claim 9 wherein the determined dose of medication is transmitted wirelessly to the drug administration system.

11. The method of claim 1 further including receiving calibration information from an in vitro glucose monitor.

12. The method of claim 11 wherein processing the received plurality of analyte related signals includes calibrating the plurality of analyte related signals based on the received calibration information.

13. The method of 1 wherein the telephone connection includes a telephone interface.

14. The method of claim 1 further including outputting the indication associated with the determined acceleration of the analyte level increase or decrease reaching or exceeding the threshold value.

15. The method of claim 1 further including activating an alarm when the determined acceleration of the analyte level increase or decrease reaches or exceeds the threshold value.

16. The method of claim 1 wherein the threshold value is associated with an impending hypoglycemic condition, an impending hyperglycemic condition, a hypoglycemic condition, or a hyperglycemic condition.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2013
From: E. HELLER & COMPANY, INC.
To: THERASENSE, INC.
Reel/Frame 029743/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2013
From: SAY, JAMES; TOMASCO, MICHAEL F.; HELLER, ADAM; ARIA, BEHRAD; HELLER, EPHRAIM; PLANTE, PHILLIP JOHN; VREEKE, MARK S.; FRIEDMAN, KEITH A.; COLMAN, FREDRIC C.; GAL, YORAM
To: E. HELLER & CO.
Reel/Frame 029743/0633 →
CHANGE OF NAME Recorded Feb 2, 2013
From: THERASENSE, INC.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 029743/0689 →
Continuity (4)
Continuation 10420057 · Apr 18, 2003
Continuation 09667199 · Sep 21, 2000
Continuation 09070677 · Apr 30, 1998
Related Publication 20100106001A1 · Apr 29, 2010